Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4589487
Max Phase: Preclinical
Molecular Formula: C63H103N13O16S2
Molecular Weight: 1362.73
Molecule Type: Unknown
Associated Items:
ID: ALA4589487
Max Phase: Preclinical
Molecular Formula: C63H103N13O16S2
Molecular Weight: 1362.73
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCC(=O)NCCOCCOCCNC(=O)CSC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Standard InChI: InChI=1S/C63H103N13O16S2/c1-4-5-6-7-8-9-10-11-12-13-14-18-54(81)67-26-29-91-31-32-92-30-27-68-56(83)40-94-38-48-61(88)71-44(24-25-51(64)78)58(85)72-47(36-52(65)79)60(87)75-49(39-93-33-16-19-55(82)70-46(59(86)74-48)35-42-20-22-43(77)23-21-42)63(90)76-28-15-17-50(76)62(89)73-45(34-41(2)3)57(84)69-37-53(66)80/h20-23,41,44-50,77H,4-19,24-40H2,1-3H3,(H2,64,78)(H2,65,79)(H2,66,80)(H,67,81)(H,68,83)(H,69,84)(H,70,82)(H,71,88)(H,72,85)(H,73,89)(H,74,86)(H,75,87)/t44-,45-,46-,47-,48-,49-,50-/m0/s1
Standard InChI Key: KMCIQFWUAHRWSM-OLLPCQKTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1362.73 | Molecular Weight (Monoisotopic): 1361.7087 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Pflimlin E, Zhou Z, Amso Z, Fu Q, Lee C, Muppiddi A, Joseph SB, Nguyen-Tran V, Shen W.. (2020) Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects., 63 (1): [PMID:31850759] [10.1021/acs.jmedchem.9b01862] |
Source(1):